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Pantothenate kinase-associated neurodegeneration is not a synucleinopathy
Aims: Mutations in the pantothenate kinase 2 gene
(PANK2) are responsible for the most common type of
neurodegeneration with brain iron accumulation
(NBIA), known as pantothenate kinase-associated neuro-
degeneration (PKAN). Historically, NBIA is considered a
synucleinopathy with numerous reports of NBIA cases
with Lewy bodies and Lewy neurites and some cases
reporting additional abnormal tau accumulation.
However, clinicopathological correlations in genetically
proven PKAN cases are rare. We describe the clinical,
genetic and neuropathological features of three unre-
lated PKAN cases. Methods: All three cases were geneti-
cally screened for the PANK2 gene mutations using
standard Sanger polymerase chain reaction sequencing.
A detailed neuropathological assessment of the three
cases was performed using histochemical and immuno-
histochemical preparations. Results: All cases had classi-
cal axonal swellings and Perls’ positive iron deposition in
the basal ganglia. In contrast to neuroaxonal dystrophies
due to mutation of the phospholipase A2, group VI
(PLA2G6) gene, in which Lewy body pathology is wide-
spread, no a-synuclein accumulation was detected in any
of our PKAN cases. In one case (20-year-old male) there
was significant tau pathology comprising neurofibrillary
tangles and neuropil threads, with very subtle tau pathol-
ogy in another case. Conclusions: These findings indicate
that PKAN is not a synucleinopathy and, hence the
cellular pathways implicated in this disease are unlikely
to be relevant for the pathomechanism of Lewy body
disorders.
Keywords: a-synuclein, Lewy body, neurodegeneration with brain iron accumulation, neurofibrillary tangles, pantoth-
enate kinase 2, tau
Introduction
Neurodegeneration with brain iron accumulation (NBIA)
encompasses several progressive movement disorders
with excessive iron accumulation in the brain paren-
chyma, especially in the basal ganglia. Patients with NBIA
can present with symptoms and signs such as ataxia, dys-
tonia, muscle rigidity, dysarthria, retinal or optic degen-
eration and dementia [1]. Classification of NBIA patients
has gradually evolved due to advances in clinical, patho-
logical and most importantly the genetic understanding
of these disorders. Earlier literature described several
common groups, including the infantile or classical neu-
roaxonal dystrophy (iNAD), also known as Seitelberger
disease, the Hallervorden–Spatz syndrome (HSS) [2,3] and
also late infantile or juvenile forms [4]. iNAD has an onset
before the age of 6 years and is usually more aggressive as
Correspondence: Tamas Revesz, Queen Square Brain Bank, Depart-
ment of Molecular Neuroscience, UCL Institute of Neurology, Queen
Square, London WC1N 3BG, UK. Tel: +44 203 448 4232, Fax:
+44 203 448 4486; E-mail: t.revesz@ucl.ac.uk
1Equally contributing authors.
© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
121
Neuropathology and Applied Neurobiology (2013), 39, 121–131 doi: 10.1111/j.1365-2990.2012.01269.x
patients also have developmental and neurological mani-
festations, whereas in the later onset form of the disease
patients often develop psychiatric features and slowly pro-
gressive neurological problems [5,6].
Prior to the identification of disease genes the diagnosis
of NBIA was based on clinical features and ultimately the
neuropathological examination, which demonstrated dis-
seminated axonal swellings with various amounts of iron
accumulation in structures such as the pallidum and in
some cases also in the pars reticulata of the substantia
nigra [4,7–9]. As a result of the common finding of
axonal swellings in both HSS and iNAD, these conditions
were often considered phenotypic variants of the same
underlying disorder [4].
The recognition that mutations of the pantothenate
kinase 2 (PANK2) gene are the commonest cause of NBIA
[10], also known as pantothenate kinase-associated neu-
rodegeneration (PKAN), NBIA type 1 or HSS, has signifi-
cantly advanced our understanding of this disorder [11].
PANK2 has an essential role in regulating co-enzyme A
biosynthesis, catalysing the cytosolic phosphorylation of
pantothenate (vitamin B5), N-pantothenoylcysteine and
pantetheine and is involved in ceramide metabolism
[12,13]. PKAN is inherited in an autosomal recessive
manner and is estimated to be responsible for approxi-
mately 50% of all NBIA cases [11]. Patients with PKAN
usually have the eye-of-the-tiger sign in the globus palli-
dus on T2-weighted magnetic resonance imaging (MRI)
scans, which consists of a hyperintense central region,
corresponding to tissue necrosis or oedema surrounded
by a hypointense zone with high iron levels [14–16].
Although initially it was thought that there is a close cor-
relation between the eye-of-the-tiger sign and PKAN, it
has been recognized that this MRI sign is not pathogno-
monic for PKAN as it may also be seen in other forms of
NBIA [17]. According to the current classification, NBIA
type 2 includes iNAD and also juvenile and adult cases
with dystonia-parkinsonism syndrome and it has been
shown to be associated with mutations in the phospholi-
pase A2, group VI (PLA2G6) gene. NBIA is also uncom-
monly associated with acoeruloplasminaemia due to
mutations in the coeruloplasmin (CP) gene [18] and neu-
roferritinopathy associated with mutations in the FTL (fer-
ritin light polypeptide) gene [19].
Since the mid-1960s there have been a number of
reports describing Lewy bodies in neurones of the pars
compacta of the substantia nigra and sometimes in neu-
rones of the locus coeruleus in HSS/NBIA [7,20,21]. In
addition, it has also been described that some HSS cases
may be associated with neurofibrillary tangle pathology
[22,23]. As a result HSS was consistently considered a
form of synucleinopathy with potential implications for
PANK2-related cellular pathways on the pathogenesis of
other Lewy body disorders, including Parkinson’s disease
[24,25]. Recently, Gregory et al. demonstrated that Lewy
body pathology is a feature of NBIA type 2 due to muta-
tions of the PLA2G6 gene [26]. Subsequently, in a detailed
neuropathological study of five additional cases with
PLA2G6 mutations, we also confirmed that a-synuclein
deposition is a consistent phenomenon in cases with
PLA2G6 mutations and also that the Lewy body pathol-
ogy may be severe and extensive with a pattern similar to
that seen in end-stage Lewy body disorders including
dementia with Lewy bodies and Parkinson’s disease [27].
The aims of this current study were twofold. First we
wished to report the neuropathological features of three
previously unreported and genetically proven PKAN
cases. Second, in view of the literature data indicating a
link between PANK2 and Lewy body disorders, we wished
to establish the incidence of a-synuclein and tau patholo-
gies in this group of cases as, apart from a recent report
[28], no other pathological description of genetically
proven cases is available in the literature.
Material and methods
Material
This project was approved by the Joint Local Research
Ethics Committee of the National Hospital for Neurology
and Neurosurgery and the UCL Institute of Neurology.
Tissue was received from the Brain and Tissue Banks
for Developmental Disorders, Baltimore (BTBDD) where
brains are obtained and stored with appropriate consent.
Clinical details, kindly provided by the BTBDD of three
PANK2 mutation cases. To our knowledge, none of the
cases have been previously reported.
Genetics
Techniques and primer sequences used in this study have
been previously reported by our laboratory [27]. In brief,
all exons of the PANK2 gene were sequenced using stan-
dard Sanger polymerase chain reaction sequencing on an
ABI 3730XL machine (Applied Biosystems, Inc., Foster
City, CA, USA) with sequence alignment and repeat analy-
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sis in all mutations. The PANK2 gene was also screened in
100 controls, which were all negative for these variants.
PANK2 primer sequences are in Supplementary Table S1.
Additional movement disorder and NBIA genes were also
sequenced to rule out possible mutations, these included
the Dyt1, PLA2G6 and ferritin light chain genes.
Neuropathology
Brain regions from three cases with the clinical diagnosis
of HSS were available from BTBDD and examined in the
laboratory of the Queen Square Brain Bank for Neurologi-
cal Disorders, using routine histological and immunohis-
tochemical methods. Regions available included frontal
and temporal necortex, hippocampus with parahippoc-
ampus, amygdala, basal ganglia, midbrain with substan-
tia nigra, pons and medulla. No cerebellar blocks were
available for this study. In brief, 7 mm thick sections of
paraffin embedded tissue blocks were deparaffinized and
rehydrated through graded alcohols. Sections were placed
in 0.3% H2O2 in methanol to block endogenous peroxidase
activity. Antigen retrieval of masked antigen epitopes was
achieved either by pressure cooking in citrate buffer (pH
6.0) for 10 min, incubation in 99% formic acid for 10 min
or incubation in Proteinase K solution for 10 min (see
Supplementary Table S2) this was followed by 10% non-
fat milk solution to prevent non-specific antibody binding.
The appropriate primary antibody was applied (see
Supplementary Table S2), followed by an anti-mouse or
anti-rabbit secondary antibody (Dako, Ely, UK) as appro-
priate. Subsequently avidin-biotin complex Elite kit
(Vector, Peterborough, UK) was applied and colour was
developed by diaminobenzidine/H2O2. Sections were
finally counterstained with Mayer’s haematoxylin. In
addition, Perls’ Prussian blue stain for iron and Gallyas
silver staining were performed.
Results
Genetics
Case 1 and case 2 were compound heterozygous for the
His283Gln and Gly521Arg mutations and the Del423/
424Cys and Gly521Arg mutations, respectively. Case 3
was homozygous for the Gly521Arg mutation (Table 1).
All three mutations have been described previously and
are predicted to be pathogenic according to the sequence
change, conservation among lower species and their
absence in controls (Table 1).
Clinical data
Table 1 shows a summary of the main clinical data in the
three cases. Cases 1 and 2 were diagnosed with iNAD with
Table 1. PANK2 gene mutations and clinical features
Demographics and genetics
Case Sex Ethnicity Age of onset Age at death Nucleotide change
Amino acid
change
PANK2
gene location
1 Female American Caucasian 2 years 10 years Heterozygous 847C>G His283Gln Exon 2
Heterozygous 1561G>A Gly521Arg Exon 6
2 Female American Caucasian 6 months 10 years Heterozygous Del1267-9 Del423/424Cys Exon 4
Heterozygous 1561G>A Gly521Arg Exon 6
3 Male American Caucasian Childhood 20 years Homozygous 1561G>A Gly521Arg Exon 6
Clinical details
Case First clinical symptom Ataxia Dystonia
Pigmentary
retinopathy Main clinical symptoms
1 Balance problems
and falling
Severe later
in disease
Yes Yes Spasticity, dysarthria progressive rigidity with
dyskinesia, dystonia and autistic
2 Developmental
delay
Moderate Yes Yes Developmental milestones delayed, weakness, dystonia
with hypotonia, impaired co-ordination
3 Details not available Moderate Yes Yes Rigidity, painful spasms, nystagmus, severe contractures
Del, deletion.
Absence of Lewy body pathology in PKAN 123
© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
NAN 2013; 39: 121–131
disease onset at 2 years and 6 months of age, respectively.
Case 3 began to show the first symptoms at the age of 10
and was considered to suffer from juvenile NAD.
Case 1 was a Caucasian girl, whose initial development
in early infancy was normal, but she developed balance
problems and falls at around 2 years of age. Subsequently
she showed a delay in her physical development, suffered
from increased tone in her limbs, developed dystonia and
was found to have pigmentary retinopathy. As a toddler
the differential diagnosis also included autism as she had
speech delay and by the age of 10 year she had lost all
speech. In later life around 6 years of age she developed
severe spasticity of her upper and lower limbs with the
right side being more affected than the left, progressive
rigidity with dyskinesia and dystonia and later she also
suffered from seizures. She was unresponsive to Sinemet
and Artane. Other symptoms included difficulties with
swallowing and chewing (due to bulbar spasticity) and
bowel movements. Routine examination and detailed
blood and urine screening were negative apart from posi-
tive antigliadin antibodies. An MRI scan at 8 years of age
was typical for PKAN with the eye of the tiger sign seen on
T2 weighted images. Later on she required a gastrostomy
tube for feeding her fluids and food. She died at the age of
10 years from respiratory complications of the disorder.
Case 2 was a Caucasian girl, who at 6 months of age
was found to be weak and unable to roll over or crawl. At
15 months she was diagnosed with ‘mild cerebral palsy’,
spasticity and dystonia. At the age of 2 years she began to
have visual problems and was found to have pigmentary
retinopathy. She was documented to be underweight and
showing rigidity, dystonia with hypertonia and impaired
co-ordination at the age of 4 years. She had two unaf-
fected siblings; however, there was a paternal second
cousin with ‘amyotrophic lateral sclerosis’-like neurologi-
cal problems and the maternal grandmother had parkin-
sonism. She was extensively investigated, but blood and
CSF did not show any abnormalities. An MRI scan showed
increased signal in the globus pallidus with a hypointense
periphery (‘the eye of the tiger sign’) on T2 weighted
images, but sparing of the substantia nigra. Electroen-
cephalogram showed low background with low voltage
but no epileptiform discharges. Electroretinogram showed
no rod and cone discharges and was essentially flat. At
the age of 9 she was documented to have uncontrollable
writhing movements, dysarthria, seizures, and difficulty
with swallowing, rigidity, spasticity and spasms in all
extremities and tremor. A number of treatments were
tried including Prednisolone, L-Dopa, Artane, Carbatrol,
Selegiline and Baclofen without any benefit. Subsequently
her condition further deteriorated and she developed dys-
arthria and feeding difficulties requiring a gastrostomy
tube. Towards the end of her life she suffered episodes of
respiratory insufficiency with aspiration pneumonia.
Case 3. This Caucasian boy presented in late childhood
with dystonia and rigidity, although no information is
available about the exact age when his first symptoms
began. At the age of 10 years he had an MRI scan, which
showed a hypointense globus pallidus and a hyperintense
area anterior and medial to the globus pallidus indicative
of ‘the eye of the tiger’ sign seen on T2 weighted images.
He responded poorly to medication and by the age of 11
years his movement disorder was severe enough to
warrant a left pallidotomy, followed by a right pallidotomy
a year later, to relieve the main features of severe dystonia
and painful muscle spasms and rigidity. Despite surgery
and medical therapy he continued to deteriorate. Two
months before death he was noted to have very severe
contractures, reduced facial expression although he
would smile on some occasions, pigmentary retinopathy
in both fundi and nystagmus on horizontal gaze. His
reflexes were difficult to obtain due to the severe contrac-
tures and his plantars were unresponsive. He was admit-
ted to and died in hospital with ‘double pneumonia’ a few
weeks short of 21 years of age.
Neuropathology
Macroscopic findings In all three cases the weight of the
unfixed brains was in the normal range (case 1: 1380 g;
case 2: 1225 g; case 3: 1330 g). The leptomeninges and
the arteries of the circle of Willis, the major arterial
branches and the superficial veins were unremarkable.
There was no cerebral or cerebellar cortical atrophy. At
brain slicing the cortical ribbon was well preserved and
the ventricular system was unremarkable. The globus
pallidus showed rusty discolouration and reduction in
size in all three cases. Sections of the brainstem showed
pale substantia nigra and locus coeruleus consistent
with age.
Histological findings Table 2 summarizes the main patho-
logical features of the three PKAN cases. As there were
only quantitative differences in the microscopic appear-
ances between the cases, the microscopic findings are
described together.
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The neocortical hexalaminar architecture was pre-
served throughout, although there was astrogliosis in
neocortex, entorhinal cortex and also subcortical white
matter in all three cases. These changes were of moderate
degree in both the frontal and temporal regions in case 3
and were mild in cases 1 and 2. There was marked astro-
gliosis in the hippocampal end-folium in case 1, which was
mild in cases 2 and 3. Involvement of the globus pallidus
was the major finding in all cases. In case 1 there was
marked myelin pallor, axonal loss (Figure 1a,c,d) and
prominent vacuolation of the neuropil together with a
significant increase in number of reactive astrocytes and
foamy macrophages in some of the vacuoles (Figure 2b).
In case 2 the morphological abnormalities of the globus
pallidus were similar, but considerably milder while in case
3 these were very severe with cavitation involving both
the internal and external segments of this nucleus sur-
rounded by a significant degree of astrogliosis. Loss of
globus pallidus neurones of various degrees was seen in all
three cases (case 3 > case 1 > case 2). The extent of the
Table 2. Semiquantitative summary of tau pathology, axonal swellings and gliosis in three cases with pantothenate kinase-associated
neurodegeneration
Brain region
Case 1 (4561) Case 2 (4733) Case 3 (5097)
Tau AS Gliosis Tau AS Gliosis Tau AS Gliosis
Frontal neocortex - + ++ - - + +++ - ++
Temporal neocortex - + + - + + + - ++
Globus pallidus - +++ +++ - + ++ - + +++
Putamen - ++ ++ - + ++ - - +++
Putamen pencil fibres - ++ - - ++ - - - -
Caudate - + ++ - + ++ - - +++
Caudate pencil fibres - ++ - - + - - - -
Meynert nucleus - - - - - - + + ++
Hippocampus * + ++ - + ++ - + +
Subiculum - + + - - + - - -
Entorhinal/transentorhinal cortex - - + - + + +++ - +
Fusiform gyrus - - + - + + + - +
Amygdala N/A N/A N/A - - - +* + +
Substantia nigra - + - - + - + + +
Pons - - - - - + - ++ +
Cuneate and gracile nuclei - + - - - - - + +
The severity of tau pathology, axonal swellings and gliosis was assessed semi-quantitatively.
*Tau positive neuropil threads are present, but no neurofibrillary tangles are seen.
-, absent, +, occasional/mild, ++, moderate, +++, severe.
AS, axonal swellings; N/A, not available.
Figure 1. Involvement of the globus pallidus (arrows) in neurodegeneration with brain iron accumulation type 1 due to mutation of the
PANK2 gene. Rarefaction of the neuropil (a) is accompanied by iron deposition (b), myelin (c) and axonal loss (d). (a) Haematoxylin and
eosin, (b) Perls’ iron, (c) myelin basic protein (CD94) immunohistochemistry and (d) phosphorylated neurofilament heavy chain (RT97)
immunohistochemistry. Bar on a represents 4000 mm on a–d.
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iron deposition, which was most severe in case 1, was best
appreciated on Perls’ stain utilizing the Prussian blue
reaction (Figure 1b). This also showed that iron pigment
was associated with astrocytes and microglia and was also
seen to accumulate in macrophages, mostly around small
blood vessels (Figure 2d). The presence of diffuse, dust-like
haemosiderin deposition, finely impregnating the neuropil
of the globus pallidus was also a feature (Figure 2d).
Varying numbers of large eosinophilic structures with a
granular appearance, measuring between 20 mm and
70 mm and most numerous in case 1 (Figure 2a), were
seen in all cases (case 1 > case 3 > case 2). Overall the
Figure 2. Main microscopic findings in neurodegeneration with brain iron accumulation (NBIA) type 1 are illustrated by the findings in
case 3. Neuroaxonal dystrophy is centred on the globus pallidus and basal ganglia. (a–c) Axonal swellings ranged from relatively small
(arrowheads) to large structures (arrows), which are reminiscent of the ovoid bodies in superficial siderosis. (b) In the globus pallidus small
axonal swellings (arrowheads) are seen to be surrounded by a thin layer of myelin (insert). Large vacuoles (arrows) seen in the close vicinity
of axonal swellings are likely to represent resorption of swellings. Significant deposition of iron in the globus pallidus is a constant feature.
Diffuse, dust-like deposition of iron pigment (asterisk) while the pigment is coarse elsewhere including in perivascular macrophages
(arrowhead). The insert on d demonstrates iron deposition in a typical ovoid body. (e,f) Axonal swellings (arrowheads) were immunoreactive
for phosphorylated neurofilament heavy chain and amyloid precursor protein (insert on f). (g and insert on g) The large axonal swellings
(ovoid bodies) (arrows) are strongly immunoreactive for ubiquitin and can be numerous in the globus pallidus in NBIA type 1. Tau
immunohistochemistry demonstrates a cluster of neurofibrillary tangles and a dense meshwork of neuropil threads in the frontal cortex (h),
a neurofibrillary tangle in the Meynert nucleus (i) and substantia nigra (j). The neurofibrillary tangles were Gallyas silver-positive (k).
(a–c) Haematoxylin and eosin, (insert on b) myelin basic protein (CD94) immunohistochemistry, (d) Perls’ preparation for iron, (e) SMI31
immunohistochemistry, (f) RT97 immunohistochemistry, (insert on f) amyloid precursor protein immunohistochemistry, (g) ubiquitin
immunohistochemistry, (h–j) tau (AT8) immunohistochemistry, (k) Gallyas silver impregnation. Bar on a represents 30 mm on a–d, f, h–k,
insert on g and 20 mm on e, inserts on b, d, f.
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morphological appearances of these structures were
similar to those described as ovoid bodies in superficial
siderosis. These structures were strongly ubiquitin-
positive often with a granular staining pattern, but to a
lesser extent for p62 (Figure 2g). Occasional ovoid bodies
were neurofilament-positive. Perls’ preparation demon-
strated that a proportion of the ovoid bodies showed either
a weak diffuse or a more granular staining pattern
(Figure 2d, insert). The presence of axonal spheroids, the
size of which varied between 10 mm and 30 mm, was a
prominent feature of all three cases, although there was
some variation in their numbers between the cases (case
1 > case 2 > case 3). They were most numerous in the
globus pallidus and were also readily found in the medial
putamen, bordering the external pallidum, in the pencil
fibres of the striatum and the grey matter bridges
interconnecting the putamen and caudate nucleus
(Figure 2b,c). In our cases the axonal spheroids were best
demonstrated with phosphorylation dependent anti-NF-H
antibodies (RT97 and SMI31) (Figure 2e,f), although the
intensity of their staining was somewhat variable. They
were also seen on the APP immunohistochemical prepa-
rations (Figure 2f, insert). In contrast to ovoid bodies,
axonal spheroids were weakly ubiquitin-positive. Myelin
basic protein immunohistochemistry demonstrated loss of
myelin sheaths in the pallidum and that small axonal
swelling were surrounded by a thin layer of myelin
(Figures 1c and 2b, insert).
There was no cell loss in the pars compacta of the sub-
stantia nigra or other brainstem nuclei in the midbrain,
pons or medulla in the three cases studied. In particular,
a-synuclein immunohistochemistry, carried out using
three different antibodies on tissue sections of cerebral
cortex, basal ganglia with the Meynert nucleus, brain-
stem, including substantia nigra and locus coeruleus was
entirely negative. However, in case 3 tau immunohis-
tochemistry using the phosphorylation-dependent AT8
anti-tau antibody recognizing Ser202/Thre205, demon-
strated neurofibrillary tangles and neuropil threads in the
frontal cortex and pre-a neuronal clusters of the entorhi-
nal cortex. An occasional neurofibrillary tangle was also
seen in the temporal neocortex, and the Meynert nucleus
(Figure 2h,i). Tau isoform-specific immunohistochemistry
showed that tau in the neurofibrillary tangles and neuro-
pil threads were composed of both 3-repeat and 4-repeat
tau isoforms. Both the neurofibrillary tangles and neuro-
pil threads were also labelled with the AT100 anti-tau
antibody and were ubiquitin, p62 and Gallyas silver-
positive (Figure 2k). In case 1 an occasional tau-positive
neuropil thread was noted in the hippocampus. None of
the cases had any Ab peptide deposition in parenchyma or
blood vessels.
Discussion
In this comparative study we have provided clinical,
genetic and pathological data for three cases with PKAN/
NBIA type 1. Our cases 1 and 2 had a classical clinical
presentation whereas case 3 presented later in life with a
dystonic rigid picture consistent with juvenile NAD
[11,13]. As there is a significant overlap between NBIA
type 1 and type 2 cases in clinical presentation, both the
PLA2G6 and PANK2 genes were sequenced, which
showed that all three cases are associated with mutations
of the PANK2 gene. These were compound heterozygous
mutations in cases 1 and 2 and homozygous in case 3. All
three mutations are predicted to be pathogenic and were
not present in our cohort of appropriate controls.
In keeping with the classical description of PKAN/NBIA
type 1 neuropathological examination of all three cases
demonstrated axonal spheroids and neuronal cell loss
with parenchymal damage of the neural parenchyma of
the globus pallidus. Deposition of Perls’ positive iron
pigment and the presence of various numbers of ovoid
bodies were also constant features. Axonal swellings,
which in this study were best demonstrated by high
molecular weight phosphorylated neurofilament immu-
nohistochemistry and showed variable reactivity to ubiq-
uitin and APP, were most numerous in the globus pallidus,
followed by the medial putamen, including pencil fibres
adjacent to the globus pallidus and grey matter bridges of
the striatum interconnecting the putamen with the
caudate nucleus. In another, recently reported series of
genetically confirmed PKAN cases the neuropathological
changes were also largely centred on the globus pallidus
and surrounding structures [28]. This observation is in
contrast with the rather widespread distribution of neu-
roaxonal swellings that is present in NBIA type 2 with
PLA2G6 mutations, in which brain iron accumulation is
rather variable and axonal swellings are frequent in the
globus pallidus, brainstem nuclei as well as spinal cord
and cerebellar degeneration may also be a prominent
feature [26,27]. Axonal swellings are a central feature of
both NBIA type 1 and type 2, although the mechanisms
leading to their formation remain to be understood.
Axonal swellings are thought to be due to defects in
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axonal transport or membrane integrity, which in NBIA
type 2 is likely to be related to the critical role calcium-
independent PLA2 enzymes play in cell membrane
homeostasis [29]. As no pathological involvement of the
basal ganglia can be seen in the PANK2 knock-out mice
model so far reported [30], our understanding of how
neuroaxonal swellings are formed in NBIA is largely
reliant on data from PLA2G6 knock-out mouse models
[31,32]. These studies confirm that axonal swellings arise
from degeneration of swollen axons or synaptic terminals
while the large vacuoles, which were seen in our PKAN
cases and have also been described in the PLA2G6 knock-
out animal models, are thought to occur as a result of
resorption of spheroids via a cellular process involving
ubiquitination [32]. The relevance of the axonal spheroids
for clinical disease is underpinned by the data indicating
that in the PLA2G6 mouse model the onset of motor
impairment correlates with a significant increase in
number of the ubiquitin-positive spheroids in nearly all
brain regions [31].
An electron microscopic study of neuroaxonal dystro-
phies has demonstrated two types of axonal changes in
HSS according to the size and ultrastructural composition
of the axonal swellings [33]. According to this study the
size of the axonal swellings varied between 20 mm and
70 mm. The ‘small’ axonal swellings are surrounded by a
myelin sheath, which is also confirmed by our light
microscopy study, and are composed of dense and vesicu-
lar bodies, degenerating mitochondria and amorphous
material. The ‘large’ axonal swellings, measuring up to
70 mm, are not surrounded by a myelin sheath and
contain predominantly dense bodies and abnormal mito-
chondria [33]. Similar to a recent study of PKAN cases by
Kruer et al. [28] we were also able to confirm the presence
of often numerous eosinophilic, ubiquitin-positive struc-
tures in the globus pallidus affected by iron deposition,
which correspond to the ‘large’ dystrophic axons
described and illustrated by Malandrini et al. [33]. In our
cases the size of the majority of these structures varied
between 20 mm and 40 mm with a few measuring up to
70 mm. Their morphological features are identical to the
‘ovoid bodies’ described in association with severe haemo-
siderin deposition such as that seen in superficial siderosis
or in the vicinity of cavernous haemangiomas accompa-
nied by chronic or repetitive haemorrhage [34]. The simi-
larity in this aspect of the pathology between diverse
conditions such as NBIA and superficial siderosis indicates
that ‘ovoid bodies’ can occur irrespective of whether the
iron overload is blood derived or it is due to abnormal iron
homeostasis such as that associated with PKAN. The
notion that such structures may be seen in the absence of
blood derived iron deposition is further supported by the
finding of structures with morphological appearances
similar to ‘ovoid bodies’ in various forms of Parkinsonian
disorders such as Parkinson’s disease and progressive
supranuclear palsy with degeneration of the substantia
nigra and significant iron deposition (data not shown). As
far as the origin of these structures is concerned Kruer
et al. [28] suggested that such large granular and
ubiquitin-positive structures (‘ovoid bodies’) represent
degenerating neurones. As an alternative hypothesis an
axonal origin of these structures was previously proposed,
which would be supported by their description in the crus
cerebri or the eighth cranial nerve affected by severe hae-
mosiderin deposition in superficial siderosis [34,35].
Further detailed studies are required to establish the origin
of the ‘ovoid bodies’ and their relationship to the cellular
mechanisms involved in iron regulation in different forms
of NBIA.
In view of the importance of the suspected link between
PANK2 and a-synuclein aggregation and Lewy body for-
mation [24] and the potential association of PANK2 with
tau aggregation, one of the major aims of our study was to
investigate whether Lewy body or neurofibrillary tangle
pathology is present in any of our genetically proven
PKAN cases. Since the discovery that distinct genetic
abnormalities define the two major forms of NBIA pre-
senting with NAD, cases with PLA2G6 mutations have
been shown to be closely associated with often severe,
a-synuclein and tau pathologies [26,27]. However, it has
remained uncertain whether NBIA type 1 cases with
mutations in the PANK2 gene would also show a similar
association. The information provided by the recent study
of Kruer et al. [28] and by our current study now clearly
indicates that Lewy body pathology is not a feature of
PKAN/NBIA type 1. It is of interest that we were able to
confirm focal tau pathology with neurofibrillary tangles
and neuropil threads in cerebral cortex, anterior temporal
mesocortex and the Meynert nucleus in our case 3, who
had a later disease onset and died at the age of 20 years. In
addition, occasional neuropil threads were seen in case 1.
Not only were the neurofibrillary tangles and neuropil
threads stained with the phosphorylation-dependent AT8
antibody in our case 3, but they were also labelled with the
3-repeat and 4-repeat tau-specific antibodies indicating
that, as in paired helical filament tau, both major classes of
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tau isoforms contribute to the tau inclusions in our PKAN
case. Furthermore, the neurofibrillary tangles and neuro-
pil threads were also labelled with the AT100 anti-tau
antibody and stained by the Gallyas silver method, indicat-
ing filamentous tau pathology [36]. The fact that case 3
was the oldest in our series may be important and indicate
that age is an important factor in the initiation of NBIA-
associated tau pathology. It is of note that this is in con-
trast to our previously reported observation indicating
that in NBIA cases associated with mutations in the
PLA2G6 gene, the tau pathology, which was severe in
three of the five pathologically studied cases, tended to be
less severe in the later onset cases while all cases had
severe Lewy body pathology [27].
Our study further defines the clinical spectrum and
neuropathology of PANK2-associated NBIA type 1 and
provides a comparison to the NBIA type 2 cases associated
with PLA2G6 mutations. The clinical phenotype of the
cases with PANK2 and PLA2G6 is remarkably similar in
the initial stages of the two diseases when it would be very
difficult to differentiate the two as both have developmen-
tal delay, spasticity and dystonia. Later in the disease
course, there are clinical differences with PLA2G6 cases
having ataxia, greater Parkinsonian features and a better
response to L-Dopa. Imaging is also a way to differentiate
the two with PANK2 having the eye of the tiger sign on
MRI while PLA2G6 cases show the hypodense basal
ganglia signal. Importantly our current study has demon-
strated that Lewy body pathology is not a feature of NBIA
type 1, which is in contrast to previous confirmation
of severe a-synuclein pathology in NBIA type 2. The
presence of abnormal tau pathology could suggest an
important aetiological role of PANK2, which has
been implicated in mitochondrial function, iron and
tau [37].
Conflicts of interest
The authors declare that they have no conflict of interest.
Acknowledgements
We are grateful to the patients and families who support
the donation of tissue for research. We thank the follow-
ing for essential grant support: The Bachmann Strauss
Foundation (J. H.), The Medical Research Council (MRC.,
H. H. and J. H.; MRC fellowship to H. H.), The Michael J.
Fox Foundation (H. H. and J. H.), Ataxia UK (H. H.), The
BMA, Vera Down Award (H. H.), The MSA Trust (J. L. H.,
H. H., J. H., A. J. L., T. R.), and the Alzheimer’s Research
UK (T. R., J. L. H.) and Parkinson’s UK (T. R., J. L. H.,
A. J. L.). We thank the NICHD, Brain and Tissue Bank for
Developmental Disorder at the University of Maryland,
Baltimore, MD. The role of NICHD, Brain and Tissue Bank
is to distribute tissue, and, therefore, cannot endorse the
studies performed or the interpretation of results. The
Queen Square Brain Bank is supported by the Reta Lila
Weston Institute and by grants from the Progressive
Supranuclear Palsy (Europe) Association. This study was
partly supported by the NIHR UCLH/UCL Comprehensive
Biomedical Research Centre. This work was supported in
part by the Wellcome/MRC Parkinson’s Disease Consor-
tium grant to UCL Institute of Neurology, the University of
Sheffield and the MRC Protein Phosphorylation Unit at the
University of Dundee.
References
1 Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic
delineation of neurodegeneration with brain iron accu-
mulation. J Med Genet 2009; 46: 73–80
2 Hallervorden J, Spatz H. Eigenartige Erkrankung im
extrapyramidalen System mit besonderer Beteiligung des
Globus pallidus und der Substantia nigra: ein Beitrag zu
den Beziehungen zwischen diesen beiden Zentren. Z Ges
Neurol Psychiat 1922; 79: 254–302
3 Seitelberger F. Eine unbekannte Form von infantiler
lipoid-Speicher Krankheit des Gehirns. Eine unbekannte
Form von infantiler lipoid-Speicher Krankheit des
Gehirns. Proceedings of the 1st International Congress of
Neuropathology 1952; 3: 323
4 Seitelberger F. Neuroaxonal dystrophy: its relation to
aging and neurological diseases. In Extrapyramidal Dis-
orders. In Handbook of Clinical Neurology Vol. 5 (49). Eds
PJ Vinken, GW Bruyn, HL Klawans. Amsterdam: Elsevier
Science Publishers BV, 1986; 391–415
5 Oner O, Oner P, Deda G, Icagasioglu D. Psychotic disorder
in a case with Hallervorden-Spatz disease. Acta Psychiatr
Scand 2003; 108: 394–7
6 Sunwoo YK, Lee JS, Kim WH, Shin YB, Lee MJ, Cho IH,
Ock SM. Psychiatric disorder in two siblings with
Hallervorden-Spatz disease. Psychiatry Investig 2009; 6:
226–9
7 Defendini R, Markesbery WR, Mastri AR, Duffy PE.
Hallervorden-Spatz disease and infantile neuroaxonal
dystrophy. Ultrastructural observations, anatomical
pathology and nosology. J Neurol Sci 1973; 20: 7–23
8 Savoiardo M, Halliday WC, Nardocci N, Strada L,
D’Incerti L, Angelini L, Rumi V, Tesoro-Tess JD.
Hallervorden-Spatz disease: MR and pathologic findings.
AJNR Am J Neuroradiol 1993; 14: 155–62
Absence of Lewy body pathology in PKAN 129
© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
NAN 2013; 39: 121–131
9 Sharma MC, Aggarwal N, Bihari M, Goyal V, Gaikwed S,
Vaishya S, Sarkar C. Hallervorden spatz disease: MR and
pathological findings of a rare case. Neurol India 2005;
53: 102–4
10 Zhou B, Westaway SK, Levinson B, Johnson MA,
Gitschier J, Hayflick SJ. A novel pantothenate kinase gene
(PANK2) is defective in Hallervorden-Spatz syndrome.
Nat Genet 2001; 28: 345–9
11 Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson
MA, Ching KH, Gitschier J. Genetic, clinical, and radio-
graphic delineation of Hallervorden-Spatz syndrome. N
Engl J Med 2003; 348: 33–40
12 Hannun YA, Obeid LM. Principles of bioactive lipid sig-
nalling: lessons from sphingolipids. Nat Rev Mol Cell Biol
2008; 9: 139–50
13 Hortnagel K, Prokisch H, Meitinger T. An isoform of
hPANK2, deficient in pantothenate kinase-associated
neurodegeneration, localizes to mitochondria. Hum Mol
Genet 2003; 12: 321–7
14 Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H.
Brain MRI in neurodegeneration with brain iron accu-
mulation with and without PANK2 mutations. AJNR Am
J Neuroradiol 2006; 27: 1230–3
15 Mutoh K, Okuno T, Ito M, Nakano S, Mikawa H, Fujisawa
I, Asato R. MR imaging of a group I case of Hallervorden-
Spatz disease. J Comput Assist Tomogr 1988; 12: 851–3
16 Sethi KD, Adams RJ, Loring DW, el Gammal T.
Hallervorden-Spatz syndrome: clinical and magnetic
resonance imaging correlations. Ann Neurol 1988; 24:
692–4
17 McNeill A, Birchall D, Hayflick SJ, Gregory A, Schenk JF,
Zimmerman EA, Shang H, Miyajima H, Chinnery PF. T2*
and FSE MRI distinguishes four subtypes of neurodegen-
eration with brain iron accumulation. Neurology 2008;
70: 1614–19
18 Yoshida K, Furihata K, Takeda S, Nakamura A, Yama-
moto K, Morita H, Hiyamuta S, Ikeda S, Shimizu N,
Yanagisawa N. A mutation in the ceruloplasmin gene is
associated with systemic hemosiderosis in humans. Nat
Genet 1995; 9: 267–72
19 Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chin-
nery PF, Coulthard A, Jackson MJ, Jackson AP, McHale
DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A,
Burn J. Mutation in the gene encoding ferritin light
polypeptide causes dominant adult-onset basal ganglia
disease. Nat Genet 2001; 28: 350–4
20 Neumann M, Adler S, Schluter O, Kremmer E, Benecke R,
Kretzschmar HA. Alpha-synuclein accumulation in a
case of neurodegeneration with brain iron accumulation
type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome)
with widespread cortical and brainstem-type Lewy
bodies. Acta Neuropathol 2000; 100: 568–74
21 Wakabayashi K, Yoshimoto M, Fukushima T, Koide R,
Horikawa Y, Morita T, Takahashi H. Widespread
occurrence of alpha-synuclein/NACP-immunoreactive
neuronal inclusions in juvenile and adult-onset
Hallervorden-Spatz disease with Lewy bodies. Neuro-
pathol Appl Neurobiol 1999; 25: 363–8
22 Eidelberg D, Sotrel A, Joachim C, Selkoe D, Forman A,
Pendlebury WW, Perl DP. Adult onset Hallervorden-
Spatz disease with neurofibrillary pathology. A discrete
clinicopathological entity. Brain 1987; 110: 993–1013
23 Hartmann HA, White SK, Levine RL. Neuroaxonal dys-
trophy with neuromelanin deposition, neurofibrillary
tangles, and neuronal loss. Light- and electron-
microscopic changes in a 45-year-old woman with pro-
gressive psychomotor deterioration. Acta Neuropathol
1983; 61: 169–72
24 Bras J, Singleton A, Cookson MR, Hardy J. Emerging
pathways in genetic Parkinson’s disease: potential role of
ceramide metabolism in Lewy body disease. FEBS J 2008;
275: 5767–73
25 Dickson DW. Alpha-synuclein and the Lewy body disor-
ders. Curr Opin Neurol 2001; 14: 423–32
26 Gregory A, Westaway SK, Holm IE, Kotzbauer PT,
Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N,
Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A,
Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik
I, Gitschier J, Hayflick SJ. Neurodegeneration associated
with genetic defects in phospholipase A(2). Neurology
2008; 71: 1402–9
27 Paisan-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R,
Kidd D, Chataway J, Bhatia KP, Lees AJ, Hardy J, Revesz T,
Houlden H. Widespread Lewy body and tau accumula-
tion in childhood and adult onset dystonia-parkinsonism
cases with PLA2G6 mutations. Neurobiol Aging 2012; 33:
814–23
28 Kruer MC, Hiken M, Gregory A, Malandrini A, Clark D,
Hogarth P, Grafe M, Hayflick SJ, Woltjer RL. Novel histo-
pathologic findings in molecularly-confirmed pantothen-
ate kinase-associated neurodegeneration. Brain 2011;
134: 947–58
29 Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen
P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N,
Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A,
Bertini E, Trembath RC, Simonati A, Schanen C, Johnson
CA, Levinson B, Woods CG, Wilmot B, Kramer P,
Gitschier J, Maher ER, Hayflick SJ. PLA2G6, encoding a
phospholipase A2, is mutated in neurodegenerative dis-
orders with high brain iron. Nat Genet 2006; 38: 752–4
30 Kuo YM, Duncan JL, Westaway SK, Yang H, Nune G, Xu
EY, Hayflick SJ, Gitschier J. Deficiency of pantothenate
kinase 2 (Pank2) in mice leads to retinal degeneration
and azoospermia. Hum Mol Genet 2005; 14: 49–57
31 Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M,
Wozniak DF, Schmidt RE, Gross RW, Kotzbauer PT. Dis-
rupted membrane homeostasis and accumulation of
ubiquitinated proteins in a mouse model of infantile neu-
roaxonal dystrophy caused by PLA2G6 mutations. Am J
Pathol 2008; 172: 406–16
32 Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M,
Sakoda S, Tsujimoto Y. Neuroaxonal dystrophy caused by
130 A. Li et al.
© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
NAN 2013; 39: 121–131
group VIA phospholipase A2 deficiency in mice: a model
of human neurodegenerative disease. J Neurosci 2008;
28: 2212–20
33 Malandrini A, Cavallaro T, Fabrizi GM, Berti G, Salves-
troni R, Salvadori C, Guazzi GC. Ultrastructure and
immunoreactivity of dystrophic axons indicate a different
pathogenesis of Hallervorden-Spatz disease and infantile
neuroaxonal dystrophy. Virchows Arch 1995; 427:
415–21
34 Hughes JT, Oppenheimer DR. Superficial siderosis of the
central nervous system. A report on nine cases with
autopsy. Acta Neuropathol 1969; 13: 56–74
35 Revesz T, Barnard RO, Earl CJ. Superficial siderosis of the
central nervous system presenting with long-standing
deafness. J R Soc Med 1988; 81: 479–81
36 Clavaguera F, Bolmont T, Crowther RA, Abramowski D,
Frank S, Probst A, Fraser G, Stalder AK, Beibel M,
Staufenbiel M, Jucker M, Goedert M, Tolnay M. Transmis-
sion and spreading of tauopathy in transgenic mouse
brain. Nat Cell Biol 2009; 11: 909–13
37 Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM.
Altered neuronal mitochondrial coenzyme A synthesis in
neurodegeneration with brain iron accumulation caused
by abnormal processing, stability, and catalytic activity of
mutant pantothenate kinase 2. J Neurosci 2005; 25:
689–98
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Oligonucleotide primers used to amplify the
exonic regions and flanking introns of the phospholipase
A2, group VI (PLA2G6), the pantothenate kinase 2
(PANK2) and the ferritin light chain (FTL) genes.
Table S2. Antibodies used for immunohistochemistry
investigation.
Received 15 October 2011
Accepted after revision 7 March 2012
Published online Article Accepted on 14 March 2012
Absence of Lewy body pathology in PKAN 131
© 2012 The Authors
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society
NAN 2013; 39: 121–131
